Abarceo is a preclinical stage company, a spinout of Lund University Diabetes Center. The company has expertise in the molecular and genetic causes of beta cell dysfunction in type 2 diabetes and has identified a novel diabetes target responsible for the dysfunction, VDAC-1. By blocking VDAC-1 with a small molecule blocker beta cells are returned to a functional state in a durable and disease modifying manner allowing patients to produce sufficient insulin, naturally. The company is fundraising to support preclinical development.
View Top Employees from Abarceo Pharma| Website | http://www.abarceo.com |
| Employees | 10 (4 on RocketReach) |
| Founded | 2017 |
| Technologies |
JavaScript,
HTML,
PHP
+4 more
(view full list)
|
| Industry | Biotechnology Research, Biotechnology, Pharmaceuticals |
Looking for a particular Abarceo Pharma employee's phone or email?
Abarceo Pharma Questions
Kristian Hansen is the CEO of Abarceo Pharma.
4 people are employed at Abarceo Pharma.
Top Abarceo Pharma Employees
-
45+
-
2
Related Companies
